SEC Form 4	RM 4		STATES S	SECURITIES	ς ΔΝ	DF	XCHANG	SE CO		SION				
		ONTE	DUIAILU	Washing			OMB APPROVAL							
Section 16. Form 4 or Form 5 obligations may continue. See				F CHANGES nt to Section 16(a) of ction 30(h) of the In	of the S	ecuriti	es Exchange A		Esti	3 Number: mated average burd rs per response:	3235-0287 en 0.5			
1. Name and Address of Reporting Person [*] Marshall Ken W.				2. Issuer Name and Ticker or Trading Symbol <u>Aquestive Therapeutics, Inc.</u> [AQST]						5. Relationship of Reporting Person(s) to Iss (Check all applicable) Director 10% Ov				
(Last) (First) (Middle) C/O AQUESTIVE THERAPEUTICS, INC.				e of Earliest Transac /2023	ction (Me	onth/D	ay/Year)	X	Officer (give title below) SVP, Chief C		Other (specify below) cial Officer			
30 TECHNOLOGY DRIVE			4. If Ar	nendment, Date of (Original	Filed	(Month/Day/Ye	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) WARREN	NJ	07059								Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Rule	e 10b5-1(c) T	rans	acti	on Indica	tion	*					
				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
	•	Table I - No	n-Derivative S	ecurities Acq	uired,	Disp	posed of, c	or Ben	eficially	Owned				
Date			2. Transaction Date (Month/Day/Year)	Execution Date,		iction Instr.	4. Securities / Disposed Of (5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	erivative Conversion Date ecurity or Exercise (Month/Day/Year)		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Performance Stock Units	(1)	05/05/2023		Α		75,000		(1)	05/05/2026	Common Stock	75,000	\$0	75,000	D	

Explanation of Responses:

1. Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

Remarks:

/s/ Lori Braender, as Attorney-05/09/2023 In-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

S